Annamycin liposomal - Moleculin Biotech
Alternative Names: Annamycin-LF; Annamycin-liposomal; L-ANNA; L-annamycin; Liposomal annamycin; S-ANNALatest Information Update: 14 Jul 2024
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Aronex Pharmaceuticals; Callisto Pharmaceuticals; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Soft tissue sarcoma
- Phase I/II Acute myeloid leukaemia
- Preclinical Colorectal cancer; Liver cancer; Pancreatic cancer; Solid tumours
- Discontinued Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Triple negative breast cancer
Most Recent Events
- 10 Jul 2024 Moleculin Biotech announces the completion of its End of Phase 2 (EOP2) meeting with the US FDA for its phase Ib/II clinical trial in Acute myeloid leukemia
- 14 Jun 2024 Updated efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia released by Moleculin Biotech
- 23 May 2024 9417781 - No updates